Pharma and services specialist Clinigen (LON:CLIN) said the year gone had been another "tremendous one", which saw significant organic growth and a revenue rise of more than 45%.
All divisions of the business showed revenue and profit growth in the second half of the year to June 30, compared to the first six months.
Overall, the group's full year gross profit increased by more than 30%.
In April, the company announced the £225mln acquisition of Surrey-based Idis, a supplier of ethical unlicensed medicines, which had established Global Access (GA) and Managed Access (MA) businesses, and these operations are already providing operational and financial benefits, the firm said.
Underlying earnings (EBITDA) rose at least 20% to not less than £32.2mln (2014: £26.8mln), the firm said, while revenue was lifted to not less than £183.6mln compared to £126.6mln in 2014.
Last summer, the specialty pharma business further strengthened its oncology support portfolio with the acquisition of Ethyol from drugs giant AstraZeneca (LON:AZN).
Clinigen boss Peter George told investors on Tuesday: "This has been another tremendous year for Clinigen. Organic growth has been significant and the £225mln acquisition of Idis has propelled us into market leader position in the fast growing ethical supply of unlicensed medicines and strengthened our CTS business.
"Ethyol has strengthened the SP portfolio and we are seeing further product acquisition and complementary opportunities which supports our strategy to focus on niche, hospital-only, specialty drugs.
"The enlarged group of four operating businesses is integrating well and the Idis businesses are already contributing to the overall strong trading performance. Strategically, the focus for the current financial year is to strengthen our global footprint."
House broker Peel Hunt rates the shares a 'buy' and targets 1,000p, which is a far cry from today's price of 689p - up 3.14%.
Analyst Charles Hall notes that the £2.5mln of anticipated cost synergies from the Idis acquisition are being delivered and continue to look conservative.
"The company is also starting to see revenue synergies, such as enabling Idis to access European customers directly."
Today's results demonstrate the strong momentum at Clinigen, as well as the continuing success of its acquisition strategy, says Hall.
He expects earnings growth of more than 20% over the next three years, with the potential for incremental growth through acquisition.
Shares trade on a price-earnings multiple of 19.6 times to June 2016 estimates and fall to 16.4 times on 2017 estimates, notes the analyst, which he says "looks conservative given the rate of growth and scale of opportunity".
"Clinigen continues to be a strong cash generator and is forecast to generate >£30m next year. This ensures that the company continues to have substantial firepower to make further acquisitions," he added.